Eric Lacase
Ph.D., Researcher
Dentistry
swedish dental AB
Sweden
Biography
LaCasse, PhD, is a Research Scientist at the Children’s Hospital of Eastern Ontario Research Institute in Ottawa, Canada. Previously, he was the Head of Oncology at Aegera Therapeutics Inc. (formerly Apoptogen), where his team developed and entered into several clinical trials for cancer the first ever inhibitor-of-apoptosis (IAP) antagonist, an antisense molecule to the X-linked IAP (designated AEG35156). With the proof of principle established in those trials, his group went on to support the development of a small-molecule pan-IAP antagonist, AEG40826/ HGS1029, which was the first ever dimeric Smac mimetic to enter into clinical trials. Currently, Dr. LaCasse works with the Aegera co-founder Robert Korneluk, PhD, FRSC, in the academic research laboratory which originally identified the animal IAP gene family in 1995-6 in Ottawa. They continue to interrogate the roles that the IAPs play in cancer, signaling, apoptosis and immunity.
Research Interest
Dentistry
